Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04507997 · ClinicalTrials.gov registry record
Angelman Syndrome Natural History Study
A clinical trial of Angelman Syndrome, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 300
- Enrollment target
- 11
- Study locations
NCT04507997 is a study of Angelman Syndrome that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 300 participants, above the 99-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (203% higher). The trial reports 11 study locations across 10 states.
The verdict
NCT04507997, a study of Angelman Syndrome, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 11
- Study locations
Study Summary
The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.
Conditions Studied
Study Locations (11)
California
- Cedars-Sinai Guerin Children's - Los Angeles
- Rady Children's Hospital, San Diego - San Diego
Colorado
- Children's Hospital Colorado, Anschutz Medical Campus - Aurora
Georgia
- Emory University School of Medicine - Atlanta
Illinois
- Rush University Children's Hospital - Chicago
Massachusetts
- Boston Children's Hospital - Boston
North Carolina
- The Carolina Institute for Developmental Disabilities - Carrboro
Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt - Nashville
Alberta
- Alberta Children's Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2031-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04507997
The ClinicalTrials.gov registry entry for NCT04507997 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (203% higher). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Angelman Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT04507997 reports 11 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT04507997 about?
NCT04507997 is a clinical study titled "Angelman Syndrome Natural History Study". The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.
What is the current status of trial NCT04507997?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2018-08-01. Estimated completion is 2031-04.
What conditions does trial NCT04507997 study?
This clinical trial studies the following conditions: Angelman Syndrome.
Who is sponsoring clinical trial NCT04507997?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04507997 being conducted?
This trial has 11 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angelman Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
RECRUITING · Phase 3
-
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
RECRUITING · Phase 1
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RECRUITING · Phase 2
-
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RECRUITING · Phase 1
-
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.